小虾米
Lv5
1105 积分
2023-08-23 加入
-
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
9天前
已完结
-
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
9天前
已完结
-
The Potential Role of PD-1/PD-L1 Small Molecule Inhibitors in Colorectal Cancer with Different Mechanisms of Action
27天前
已完结
-
Small Molecule Inhibitors Targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for Cancer Immunotherapy (2020-2024)
27天前
已完结
-
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
28天前
已完结
-
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
28天前
已完结
-
Exploring the Mechanism of Curcumin-mediated Photodynamic Therapy for Systemic Lupus Erythematosus Based on Network Pharmacology
1个月前
已完结
-
Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity
2个月前
已完结
-
Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against pd-1/pd-l1
2个月前
已完结
-
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
2个月前
已完结